Low-Dose N-Butyldeoxynojirimycin (OGT 918) for Type I Gaucher Disease
- 31 March 2002
- journal article
- clinical trial
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 28 (2) , 127-133
- https://doi.org/10.1006/bcmd.2002.0497
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Treatment of Gaucher's disease with OGT 918The Lancet, 2000
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991